Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 19, 2014

View Archived Issues

Selective blockade of PTH activity by stapled peptide ATSP-10814

Clinical data show improved therapeutic efficacy of an antiasthmic drug in patient subtypes

Eisai establishes new joint research agreements for malaria

MGAT2 inhibitors designed for effects on obesity and related disorders

Series B financing at Pulmologix to fund new asthma drug

Pluristem pursues development strategy in Japan

MedGenesis and Pfizer enter into agreement for potential treatments for PD

Merck Serono and Lupin form strategic partnership targeting emerging markets

Quest PharmaTech and AD Biotech end investment agreement

Genisphere raises funds to develop targeted drug delivery technology

Trellis Bioscience and ContraFect's universal influenza treatment receives NIAID grant

Autologous mesenchymal stem cell transplant evaluated in phase I multiple sclerosis trial

Phase Ib data of synthetic cis-retinoid therapy for patients with genetic retinal defects

Clinical and preclinical data presented for a novel antibacterial, AAI-101

Treprost injection solution launched in Japan

Phase Ib/II trial of PEGPH-20 in combination with modified FOLFIRINOX to resume

Boehringer Ingelheim and CureVac to develop therapeutic cancer vaccine CV9-202

Neuraltus Pharmaceuticals' reports phase II data for NP-001

Alnylam Pharmaceuticals presents new preclinical results on ALN-CC5

Auxilium and QLT respond to Endo's acquisition proposal

Domainex discloses IKK-epsilon/TBK1 inhibitors

DPP IV inhibitors revealed in Hitgen patent

Bayer scientists report development of AKR1C3 inhibitors

Selvita describes 5-HT6 receptor antagonists

Novartis describes PI3K inhibitors in recent patent

Bayer to spin out MaterialScience polymers business and focus on healthcare and agrochemicals

Japanese approval of Aricept for dementia with Lewy bodies

FDA approves Trulicity for type 2 diabetes

Lymphoseek awarded U.S. orphan drug designation for head and neck cancers